

John-Joseph Borg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8551907/publications.pdf>

Version: 2024-02-01

13
papers

161
citations

1937685

4
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

157
citing authors

#	ARTICLE	IF	CITATIONS
1	Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?. Drug Safety, 2011, 34, 187-197.	3.2	78
2	Aducanumab for Alzheimer's disease: A regulatory perspective. Pharmacological Research, 2021, 171, 105754.	7.1	40
3	Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 181.	2.1	12
4	Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. AAPS PharmSciTech, 2018, 19, 489-511.	3.3	8
5	Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU. Expert Opinion on Drug Safety, 2021, 20, 815-826.	2.4	5
6	Improving the data quality of spontaneous ADR reports: a practical example from Malta. Expert Opinion on Drug Safety, 2022, 21, 253-268.	2.4	4
7	The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. Drug Discovery Today, 2022, , .	6.4	4
8	A review of the National pharmacovigilance system in Malta – implementing and operating a pharmacovigilance management system. Expert Opinion on Drug Safety, 2017, 16, 65-76.	2.4	3
9	Changing paradigms in bioequivalence trials submitted to the EMA for evaluation – A clinical and regulatory perspective. Saudi Pharmaceutical Journal, 2017, 25, 280-289.	2.7	3
10	Optimising bench science to withstand regulatory scrutiny. Pharmacological Research, 2019, 139, 491-493.	7.1	2
11	Comment On: 'EU's New Pharmacovigilance Legislation: Considerations for Biosimilars' Drug Safety, 2014, 37, 123-124.	3.2	1
12	QT shortening: a proarrhythmic safety surrogate measure or an inappropriate indicator of it?. Current Medical Research and Opinion, 0, , 1-30.	1.9	1
13	Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia. Drug Discovery Today, 2022, , .	6.4	0